A Phase 3 interventional study of Empagliflozin low dose and placebo in Diabetes Mellitus, Type 2 and Hypertension, sponsored by Boehringer Ingelheim. Completed at 92 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-31.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim — 2 open to participants now, 3 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Boehringer Ingelheim.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 63rd largest by enrollment of the 96 interventional ones that give a count, is one of 7 that started in 2014, is one of 50 in phase 3, and was the 84th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Australia, Canada and 3 more countries
Ages 18+
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 48 more countries
Ages 18+
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 7 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 166 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 302 across the 96 interventional studies, 10,286 across the 34 observational. Of the 125 that completed or were terminated, 109 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
1 of the studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05882071Boehringer IngelheimNon-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is designed to investigate the efficacy and safety of empagliflozin compared with placebo in hypertensive black/African Americans with type 2 Diabetes Mellitus. Since hyperglycaemia and hypertension are key risk factors for both micro- and macrovascular complications, assessment of both glucose and BP lowering effects of empagliflozin in hypertensive African American patients with type 2 Diabetes Mellitus could provide clinically highly relevant, new information for the use of empagliflozin.
Essential hypertension is four times more common in African Americans than in Caucasians.
One of the risk factors for hypertension is sodium sensitivity and approximately one third of the essential hypertensive population is responsive to sodium intake. There is a higher association of hypertension with sodium sensitivity in African American patients with type 2 Diabetes Mellitus.
The treatment duration of this trial (24 weeks) will enable assessment of the clinically relevant endpoint of a decrease in HbA1c, a well accepted measurement of chronic glycaemic control and the key secondary endpoints of decreases in systolic BP (SBP) and diastolic BP (DBP) at 12 and 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male and female black/African American patients on diet and exercise regimen who are EITHER drug-naïve (defined as absence of any oral antidiabetic therapy, glucagon like peptide-1 (GLP-1) analog or insulin for 12 weeks, 16 weeks for pioglitazone prior to randomisation) OR pre-treated with stable dose of
Exclusion criteria:
Pre-menopausal women (last menstruation \<=1 year prior to informed consent) who:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
starting dose 10mg; forced titration after 4 weeks 25mg dose
Drug: Empagliflozin low dose · Drug: Empagliflozin high dose
starting dose 10mg; forced titration after 4 weeks 25mg dose
Drug: placebo
starting dose 10mg; forced titration after 4 weeks 25mg dose
starting dose 10mg; forced titration after 4 weeks 25mg dose
starting dose 10mg; forced titration after 4 weeks 25mg dose
Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks
Change from baseline in HbA1c (%) at 24 weeks is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. Restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) model is used in the statistical analysis.
Time frame: baseline and 24 weeks
Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (SBP) at Week 12
Change from baseline in mean 24-hour ambulatory Systolic blood pressure SBP at Week 12 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. This is a key secondary endpoint
Time frame: baseline and 12 weeks
Changes From Baseline in Trough Mean Ambulatory SBP at Week 12
Changes from baseline in trough mean ambulatory SBP at Week 12 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. This is a key secondary endpoint
Time frame: baseline and 12 weeks
Change From Baseline in Body Weight at Week 24
Changes from baseline in body weight at Week 24 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. This is a key secondary endpoint
Time frame: baseline and 24 weeks
Change From Baseline in Trough Seated SBP at Week 12
Change from baseline in trough seated SBP (mmHg) at Week 12 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. This is a key secondary endpoint
Time frame: baseline and 12 weeks
Change From Baseline in Mean 24-hour Ambulatory SBP (mmHg) at Week 24
Change from baseline in mean 24-hour ambulatory SBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.
Time frame: baseline and 24 weeks
Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (DBP) at Week 12
Change from baseline in mean 24-hour ambulatory DBP (mmHg) at Week 12. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.
Time frame: baseline and 12 weeks
Change From Baseline in Mean 24-hour Ambulatory DBP (mmHg) at Week 24
Change from baseline in mean 24-hour ambulatory DBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.
Time frame: baseline and 24 weeks
Change From Baseline in Trough Seated SBP (mmHg) at Week 24
Change from baseline in trough seated SBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.
Time frame: baseline and 24 weeks
Change From Baseline in Trough Seated DBP (mmHg) at Week 12
Change from baseline in trough seated DBP (mmHg) at Week 12 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.
Time frame: baseline and 12 weeks
Change From Baseline in Trough Seated DBP (mmHg) at Week 24
Change from baseline in trough seated DBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.
Time frame: baseline and 24 weeks
In this Phase 3b, multi-centre trial, a total of 719 patients were screened by 92 centres across the United States. The first centre was initiated on 25 Jul 2014. Of the 719 screened patients, 297 patients entered the placebo run-in phase of the trial and 166 were subsequently randomised to double-blind treatment
| Milestone | Placebo | Empagliflozin 10 Mg-25mg |
|---|---|---|
| Started | 83 | 83 |
| Randomised set (rs) | 79 | 82 |
| Treated set (ts) | 77 | 80 |
| Completed | 68 | 68 |
| Not completed | 15 | 15 |
| Withdrew: Not treated | 1 | 1 |
| Withdrew: Trial stopped, reason missing | 3 | 3 |
| Withdrew: Consent withdrawn | 8 | 8 |
| Withdrew: Lost to follow-up | 3 | 3 |
Change from baseline in HbA1c (%) at 24 weeks is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. Restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) model is used in the statistical analysis.
| percentage of glycated haemoglobin | Placebo | Empagliflozin 10 Mg-25mg |
|---|---|---|
| Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks | 0.07 ± 0.14 | -0.71 ± 0.14 |
Change from baseline in mean 24-hour ambulatory Systolic blood pressure SBP at Week 12 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. This is a key secondary endpoint
| millimeter of mercury (mmHg) | Placebo | Empagliflozin 10 Mg-25mg |
|---|---|---|
| Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (SBP) at Week 12 | -0.90 ± 1.47 | -6.10 ± 1.41 |
Changes from baseline in trough mean ambulatory SBP at Week 12 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. This is a key secondary endpoint
| millimeter of mercury (mmHg) | Placebo | Empagliflozin 10 Mg-25mg |
|---|---|---|
| Changes From Baseline in Trough Mean Ambulatory SBP at Week 12 | -1.00 ± 1.89 | -6.99 ± 1.80 |
Changes from baseline in body weight at Week 24 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. This is a key secondary endpoint
| kilogram (kg) | Placebo | Empagliflozin 10 Mg-25mg |
|---|---|---|
| Change From Baseline in Body Weight at Week 24 | -0.98 ± 0.42 | -2.21 ± 0.41 |
Change from baseline in trough seated SBP (mmHg) at Week 12 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. This is a key secondary endpoint
| mmHg | Placebo | Empagliflozin 10 Mg-25mg |
|---|---|---|
| Change From Baseline in Trough Seated SBP at Week 12 | -3.94 ± 1.82 | -7.97 ± 1.83 |
Change from baseline in mean 24-hour ambulatory SBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.
| mmHg | Placebo | Empagliflozin 10 Mg-25mg |
|---|---|---|
| Change From Baseline in Mean 24-hour Ambulatory SBP (mmHg) at Week 24 | -1.94 ± 1.94 | -10.33 ± 1.85 |
Change from baseline in mean 24-hour ambulatory DBP (mmHg) at Week 12. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.
| mmHg | Placebo | Empagliflozin 10 Mg-25mg |
|---|---|---|
| Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (DBP) at Week 12 | -0.37 ± 0.90 | -3.80 ± 0.86 |
Change from baseline in mean 24-hour ambulatory DBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.
| mmHg | Placebo | Empagliflozin 10 Mg-25mg |
|---|---|---|
| Change From Baseline in Mean 24-hour Ambulatory DBP (mmHg) at Week 24 | -1.48 ± 1.24 | -6.38 ± 1.20 |
Change from baseline in trough seated SBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.
| mmHg | Placebo | Empagliflozin 10 Mg-25mg |
|---|---|---|
| Change From Baseline in Trough Seated SBP (mmHg) at Week 24 | -2.83 ± 1.82 | -10.26 ± 1.70 |
Change from baseline in trough seated DBP (mmHg) at Week 12 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.
| mmHg | Placebo | Empagliflozin 10 Mg-25mg |
|---|---|---|
| Change From Baseline in Trough Seated DBP (mmHg) at Week 12 | -2.30 ± 1.09 | -4.14 ± 1.10 |
Change from baseline in trough seated DBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.
| mmHg | Placebo | Empagliflozin 10 Mg-25mg |
|---|---|---|
| Change From Baseline in Trough Seated DBP (mmHg) at Week 24 | -1.30 ± 1.09 | -5.55 ± 1.02 |
Collected over All adverse events occurring after the first dose of trial medication up to a period of 7 days after the last dose of trial medication (i.e. end of REP); up to 25 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/80 (0%) | 4/80 (5%) | 8/77 (10.4%) |
| Empagliflozin 10 Mg-25mg | 0/82 (0%) | 3/82 (3.7%) | 12/80 (15%) |
| Event | Placebo | Empagliflozin 10 Mg-25mg |
|---|---|---|
| Chest painGeneral disorders | 1/80 | 1/82 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/80 | 0/82 |
| Cerebrovascular accidentNervous system disorders | 1/80 | 0/82 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/80 | 0/82 |
| Cardiac failure congestiveCardiac disorders | 0/80 | 1/82 |
| Drug-induced liver injuryHepatobiliary disorders | 0/80 | 1/82 |
| OverdoseInjury, poisoning and procedural complications | 0/80 | 1/82 |
| Event | Placebo | Empagliflozin 10 Mg-25mg |
|---|---|---|
| Lipase increasedInvestigations | 3/77 | 6/80 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/77 | 5/80 |
| Upper respiratory tract infectionInfections and infestations | 4/77 | 2/80 |
Full analysis set (FAS): All patients randomised, treated with at least one dose of trial drug, and with a baseline and at least one on-treatment glycated haemoglobin (HbA1c)value. The FAS was the basis for the primary efficacy analysis.
| Age, Continuous(years) | Placebo | Empagliflozin 10 Mg-25mg | Total |
|---|---|---|---|
| Mean | 57.2 ± 9.3 | 56.5 ± 9.3 | 56.8 ± 9.3 |
| Sex: Female, Male(Participants) | Placebo | Empagliflozin 10 Mg-25mg | Total |
|---|---|---|---|
| Female | 36 | 35 | 71 |
| Male | 36 | 43 | 79 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Empagliflozin 10 Mg-25mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 72 | 78 | 150 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Empagliflozin 10 Mg-25mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 72 | 78 | 150 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Baseline hemoglobin A1c (HbA1c) [%](percentage of HbA1c) | Placebo | Empagliflozin 10 Mg-25mg | Total |
|---|---|---|---|
| Mean | 8.51 ± 1.12 | 8.66 ± 0.92 | 8.59 ± 1.02 |
| Baseline estimated glomerular filtration rate (eGFR)(mL/min/1.73m²) | Placebo | Empagliflozin 10 Mg-25mg | Total |
|---|---|---|---|
| Mean | 91.49 ± 20.79 | 91.15 ± 18.95 | 91.31 ± 19.79 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2014 to primary completion in May 2017, 33 months.
Results were first posted in Jul 2018, 1 year 2 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 33 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.